- List
- By Topic
- On Map
- Search Details

"Pancreatic cancer"
Need help? See RSS Feeds
Choose a feed type:

"Pancreatic cancer" (2111 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03316599 | Recruiting | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT03316599 | 17-406 | January 17, 2018 | November 30, 2020 | November 30, 2023 | October 20, 2017 | January 23, 2018 |
|
||
2 | NCT03435289 | Recruiting | A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
24 | All | 18 Years and older (Adult, Senior) | NCT03435289 | GA CPI 613 | October 19, 2017 | November 2018 | January 2019 | February 16, 2018 | February 16, 2018 |
|
||
3 | NCT03060720 | Recruiting | Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy |
|
Observational |
|
Other / NIH |
|
|
375 | All | 18 Years and older (Adult, Senior) | NCT03060720 | 16-448 P50CA127003 |
February 24, 2017 | February 2020 | February 2022 | February 23, 2017 | February 1, 2018 |
|
||||
4 | NCT02459652 | Active, not recruiting | Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
50 | All | 20 Years to 75 Years (Adult, Senior) | NCT02459652 | JASPAC 05 | September 2012 | April 2016 | September 2018 | June 2, 2015 | June 29, 2016 |
|
||
5 | NCT02841436 | Active, not recruiting | A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
40 | All | 20 Years to 75 Years (Adult, Senior) | NCT02841436 | 201210008DIC | November 2012 | October 2018 | October 2018 | July 22, 2016 | February 23, 2017 | |||
6 | NCT02550847 | Unknown † | Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer |
|
|
Observational |
|
Other |
|
|
100 | All | 20 Years to 90 Years (Adult, Senior) | NCT02550847 | 201407052MINC | August 2014 | April 2016 | August 2016 | September 16, 2015 | April 14, 2016 |
|
|||
7 | NCT01867892 | Enrolling by invitation | A Phase II Study of Locally Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
86 | All | 20 Years to 70 Years (Adult, Senior) | NCT01867892 | T2212 | June 2013 | May 2018 | May 2019 | June 4, 2013 | June 4, 2013 | |||
8 | NCT03497819 | Active, not recruiting New |
Autologous CARTmeso/19 Against Pancreatic Cancer |
|
|
Interventional | Early Phase 1 |
|
Other |
|
|
10 | All | 18 Years to 65 Years (Adult) | NCT03497819 | YXA-meso19 | October 1, 2017 | October 31, 2019 | October 31, 2020 | April 13, 2018 | April 13, 2018 |
|
||
9 | NCT01693276 | Terminated | Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
3 | All | 18 Years and older (Adult, Senior) | NCT01693276 | UCC-GI-01 | September 2012 | June 2014 | June 2014 | September 26, 2012 | October 26, 2015 |
|
||
10 | NCT02827201 | Active, not recruiting | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine |
|
|
Interventional | Phase 2 |
|
Other |
|
|
127 | All | 18 Years to 75 Years (Adult, Senior) | NCT02827201 | PRODIGE 37 | FIRGEMAX | November 2015 | December 2017 | December 2020 | July 11, 2016 | February 23, 2017 |
|
|
11 | NCT02449967 | Withdrawn | HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
0 | All | 18 Years to 80 Years (Adult, Senior) | NCT02449967 | Pancreatic Cancer HepaSphere | May 2015 | June 2018 | June 2020 | May 21, 2015 | August 5, 2015 |
|
||
12 | NCT03180437 | Recruiting | Safety and Efficiency of γδ T Cell Against Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
30 | All | 18 Years to 75 Years (Adult, Senior) | NCT03180437 | Gd T cell and Pancreatic Ca | June 15, 2017 | June 15, 2018 | June 15, 2020 | June 8, 2017 | June 8, 2017 |
|
||
13 | NCT01346410 | Completed Has Results |
Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
1 | All | 18 Years and older (Adult, Senior) | NCT01346410 | 08-060 | September 2008 | July 2012 | July 2012 | May 3, 2011 | February 21, 2018 | February 21, 2018 |
|
|
14 | NCT03392571 | Not yet recruiting | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients |
|
|
Interventional | Phase 2 |
|
Other |
|
|
70 | All | 18 Years to 75 Years (Adult, Senior) | NCT03392571 | PCRT 17-001 | February 15, 2018 | December 30, 2020 | December 30, 2020 | January 8, 2018 | January 8, 2018 | |||
15 | NCT01587534 | Completed | Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP) |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
67 | All | 18 Years and older (Adult, Senior) | NCT01587534 | NCCCTS-11-570 | October 2011 | December 2014 | December 2014 | April 30, 2012 | April 15, 2015 |
|
||
16 | NCT02767752 | Recruiting | Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
180 | All | 18 Years and older (Adult, Senior) | NCT02767752 | GI 1604 | CHIPAC | November 2016 | November 2019 | November 2021 | May 10, 2016 | November 11, 2016 |
|
|
17 | NCT01423604 | Completed Has Results |
Study of Ruxolitinib in Pancreatic Cancer Patients |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
136 | All | 18 Years and older (Adult, Senior) | NCT01423604 | 18424-262 | RECAP | July 2011 | June 2013 | November 2016 | August 26, 2011 | February 12, 2018 | August 29, 2016 |
|
18 | NCT02650804 | Recruiting | BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT02650804 | BPM31510IV-05 | February 2016 | January 2019 | January 2019 | January 8, 2016 | March 19, 2018 |
|
||
19 | NCT03192462 | Recruiting | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
45 | All | 18 Years and older (Adult, Senior) | NCT03192462 | H-40378 TACTOPS | TACTOPS | January 18, 2018 | May 1, 2021 | November 1, 2025 | June 20, 2017 | February 2, 2018 |
|
|
20 | NCT03374293 | Recruiting | Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
21 | All | 18 Years to 75 Years (Adult, Senior) | NCT03374293 | HangzhouCH10 | December 1, 2017 | December 31, 2018 | December 31, 2018 | December 15, 2017 | December 15, 2017 |
|
||
21 | NCT02934984 | Recruiting | Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer |
|
Observational |
|
Other |
|
|
100 | All | 20 Years to 90 Years (Adult, Senior) | NCT02934984 | 2016-07-054 | July 2016 | July 2019 | January 2020 | October 17, 2016 | October 17, 2016 |
|
||||
22 | NCT02050178 | Completed | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
26 | All | 18 Years to 90 Years (Adult, Senior) | NCT02050178 | 54F28-002 | November 2013 | June 15, 2017 | June 15, 2017 | January 30, 2014 | April 9, 2018 |
|
||
23 | NCT00994721 | Completed | A Phase III Study of Pancreatic Cancer |
|
Observational |
|
Other |
|
|
147 | All | 20 Years to 75 Years (Adult, Senior) | NCT00994721 | T3207 | February 2009 | January 2016 | January 2016 | October 14, 2009 | May 4, 2016 |
|
||||
24 | NCT02005315 | Completed | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
30 | All | 18 Years to 90 Years (Adult, Senior) | NCT02005315 | 18R5-003 | September 2013 | October 2017 | November 2017 | December 9, 2013 | January 24, 2018 |
|
||
25 | NCT01396681 | Completed | Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
70 | All | 18 Years and older (Adult, Senior) | NCT01396681 | H-0412-138-006 | December 2004 | June 2011 | June 2011 | July 19, 2011 | July 19, 2011 |
|
||
26 | NCT01333631 | Unknown † | Valproic Acid With Chemoradiotherapy for Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 75 Years (Adult, Senior) | NCT01333631 | SOR513511CTIL | June 2011 | June 2013 | July 2015 | April 12, 2011 | April 12, 2011 | |||
27 | NCT01505413 | Completed | Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
33 | All | 18 Years and older (Adult, Senior) | NCT01505413 | Yun-11349 | GEMOX-T | January 2011 | December 2013 | March 2014 | January 6, 2012 | April 3, 2014 |
|
|
28 | NCT02734680 | Recruiting | IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
70 | All | 18 Years to 75 Years (Adult, Senior) | NCT02734680 | LC2015L11 | IFCSLAPC | February 2016 | February 2018 | February 2019 | April 12, 2016 | April 11, 2017 |
|
|
29 | NCT02128100 | Recruiting | Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT02128100 | BCC-RAD-13 IRB # 14.0XXX |
BCC-RAD-13 | May 2014 | May 2018 | May 2018 | May 1, 2014 | January 5, 2018 |
|
|
30 | NCT00897832 | Completed | Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer |
|
|
Observational |
|
Other / NIH |
|
|
50 | All | Child, Adult, Senior | NCT00897832 | VICC GI 0666 P30CA068485 VU-VICC-GI-0666 VU-VICC-061225 |
January 2007 | December 2007 | December 2007 | May 12, 2009 | March 5, 2013 |
|
|||
31 | NCT00897741 | Completed | Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer |
|
|
Observational |
|
Other / NIH |
|
|
10 | All | Child, Adult, Senior | NCT00897741 | CDR0000482353 P30CA022453 WSU-D-2841 WSU-HIC-091504M1E |
December 2004 | May 2008 | March 2009 | May 12, 2009 | February 11, 2014 |
|
|||
32 | NCT02894944 | Recruiting | Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
9 | All | 18 Years to 74 Years (Adult, Senior) | NCT02894944 | SNUBH-IMGPB-2016-02 | Theragene | August 2016 | July 2018 | July 2018 | September 9, 2016 | October 11, 2017 |
|
|
33 | NCT02718859 | Unknown † | Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
60 | All | 18 Years to 80 Years (Adult, Senior) | NCT02718859 | NK-pancre | March 2016 | March 2017 | March 2017 | March 24, 2016 | July 19, 2016 |
|
||
34 | NCT00837135 | Withdrawn | GI-4000 With Adoptive Transfer in Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
0 | All | 18 Years and older (Adult, Senior) | NCT00837135 | 806693 UPCC 03207 |
January 2008 | October 2009 | October 2009 | February 5, 2009 | August 17, 2016 | |||
35 | NCT00965718 | Completed Has Results |
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
20 | All | 18 Years to 75 Years (Adult, Senior) | NCT00965718 | ILC-IIT-01 | September 2009 | December 2010 | December 2010 | August 26, 2009 | December 5, 2017 | September 16, 2014 |
|
|
36 | NCT02079623 | Unknown † | Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer |
|
|
Interventional | Phase 3 |
|
Other |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT02079623 | PCaNanoK | NanoKnife | November 2013 | November 2015 | November 2015 | March 6, 2014 | March 6, 2014 |
|
|
37 | NCT00810719 | Completed Has Results |
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other / NIH / Industry |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT00810719 | UCDCC#211 232494 OSI 4132s P30CA093373 |
April 2009 | January 2013 | December 2013 | December 18, 2008 | January 10, 2018 | March 7, 2017 |
|
|
38 | NCT03187028 | Recruiting | Diet and Exercise After Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT03187028 | F141218007 | PACE | August 3, 2017 | August 31, 2018 | August 31, 2019 | June 14, 2017 | January 3, 2018 |
|
|
39 | NCT00636883 | Terminated | Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
9 | All | 18 Years to 75 Years (Adult, Senior) | NCT00636883 | RC07/031 | GEMOX-T | January 2008 | July 2012 | July 2012 | March 17, 2008 | January 22, 2014 |
|
|
40 | NCT02981641 | Recruiting | IORT Versus CCRT for Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
100 | All | 18 Years to 75 Years (Adult, Senior) | NCT02981641 | 2012AA022701 | IVCPC | December 2015 | December 2016 | December 2018 | December 5, 2016 | December 5, 2016 |
|
|
41 | NCT03117920 | Recruiting | A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
35 | All | 18 Years and older (Adult, Senior) | NCT03117920 | Minnelide002 | MinPAC | April 10, 2017 | May 15, 2018 | February 15, 2019 | April 18, 2017 | September 14, 2017 |
|
|
42 | NCT01327794 | Completed | Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer |
|
|
Observational |
|
Other / NIH |
|
|
265 | All | 18 Years and older (Adult, Senior) | NCT01327794 | CALGB-151006 U10CA031946 CDR0000698059 |
June 2011 | August 2014 | August 2014 | April 4, 2011 | June 29, 2016 |
|
|||
43 | NCT01273805 | Completed Has Results |
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT01273805 | 10-310 | January 2011 | January 2013 | February 2014 | January 11, 2011 | June 14, 2017 | June 14, 2017 |
|
|
44 | NCT02352337 | Active, not recruiting | First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem |
|
|
Interventional | Phase 2 |
|
Other |
|
|
276 | All | 18 Years and older (Adult, Senior) | NCT02352337 | PRODIGE35 | PANOPTIMOX | December 23, 2014 | December 2017 | June 2019 | February 2, 2015 | February 23, 2017 |
|
|
45 | NCT00544908 | Terminated Has Results |
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
7 | All | 18 Years and older (Adult, Senior) | NCT00544908 | 07024 P30CA033572 CHNMC-07024 BMS-CA180-114 CDR0000570288 |
September 2007 | October 2012 | October 16, 2007 | October 5, 2015 | September 17, 2015 |
|
||
46 | NCT01898741 | Unknown † | Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT01898741 | UMCU-12-628 | July 2013 | July 2016 | July 2016 | July 12, 2013 | February 3, 2015 |
|
||
47 | NCT00498225 | Completed | Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
834 | All | 20 Years to 79 Years (Adult, Senior) | NCT00498225 | 01023017 | GEST | July 2007 | July 2011 | June 2012 | July 9, 2007 | November 2, 2012 |
|
|
48 | NCT01494155 | Active, not recruiting | Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT01494155 | 11-073 | December 2011 | March 2019 | January 2020 | December 16, 2011 | April 6, 2018 |
|
||
49 | NCT01461915 | Completed | Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
61 | All | 18 Years to 75 Years (Adult, Senior) | NCT01461915 | PGX-ODSH-2011-PC1 | PGPC1 | November 2011 | December 2012 | June 2015 | October 28, 2011 | August 29, 2016 |
|
|
50 | NCT01072981 | Completed | Immunotherapy Study for Surgically Resected Pancreatic Cancer |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
722 | All | 18 Years and older (Adult, Senior) | NCT01072981 | NLG0405 OBA# 0912-1013 |
April 2010 | May 2016 | May 2016 | February 22, 2010 | September 21, 2016 |
|
† Study has passed its completion date and status has not been verified in more than two years.